QUIDELORTHO CORP Net Change in Cash
QUIDELORTHO CORP (QDEL) reported Net Change in Cash of -$46.40 million for the 6-month period ending 2026-06-28, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-07
- QUIDELORTHO CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-29 was -$29.40M, a 202.44% decline year-over-year.
- QUIDELORTHO CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-30 was $28.70M.
- QUIDELORTHO CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$40.50M, a 166.39% decline year-over-year.
- QUIDELORTHO CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-04-02 was $61.00M, a 87.10% decline year-over-year.
- QUIDELORTHO CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $71.30M.
- QUIDELORTHO CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$21.00M.
- QUIDELORTHO CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$174.40M.
- QUIDELORTHO CORP cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$508.90M, a 262.64% decline from fiscal 2022.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-28 | -$46.40M 10-Q · filed 2026-08-07 | |||
| 2026-03-29 | -$29.40M 10-Q · filed 2026-05-06 | |||
| 2025-12-28 | $71.30M 10-K · filed 2026-02-19 | |||
| 2025-09-28 | -$400.00K 10-Q · filed 2025-11-06 | |||
| 2025-06-29 | $53.20M 10-Q · filed 2026-08-07 | |||
| 2025-03-30 | $28.70M 10-Q · filed 2026-05-06 | |||
| 2024-12-29 | -$21.00M 10-K · filed 2026-02-19 | |||
| 2024-09-29 | $24.50M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | -$12.00M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | -$40.50M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$174.40M 10-K · filed 2026-02-19 | |||
| 2023-10-01 | -$144.00M 10-Q · filed 2024-11-08 | |||
| 2023-07-02 | -$114.30M 10-Q · filed 2024-08-01 | |||
| 2023-04-02 | $61.00M 10-Q · filed 2024-05-09 | |||
| 2023-01-01 | -$508.90M 10-K · filed 2025-02-27 | |||
| 2022-10-02 | -$589.60M 10-Q · filed 2023-11-02 | |||
| 2022-07-03 | -$422.20M 10-Q · filed 2023-08-09 | |||
| 2022-04-03 | $472.70M 10-Q · filed 2023-05-04 | |||
| 2022-01-02 | $312.90M 10-K/A · filed 2024-08-01 | |||
| 2021-10-03 | $88.50M 10-Q · filed 2022-11-04 | |||
| 2021-07-04 | $103.30M 10-Q · filed 2022-08-05 | |||
| 2021-01-03 | $437.10M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |